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Abstract 
Background: Cervical cancer is the sixth most common cancer in Chinese women. A standard treatment modal‑
ity for cervical cancer is the combination of surgery, chemotherapy, external‑beam radiotherapy and intracavitary 
brachytherapy. The aim of this study was to retrospectively assess the long‑term treatment outcomes of patients with 
cervical cancer who were treated with californium‑252 neutron brachytherapy combined with external‑beam radio‑
therapy plus concurrent chemotherapy.
Methods: We retrospectively analyzed the medical records of 150 patients with primary stages IB‑IVB cervical cancer 
who received neutron brachytherapy combined with external‑beam radiotherapy concurrently with cisplatin chemo‑
therapy. All patients were followed up. Using an actuarial analysis, patient outcomes and treatment‑related adverse 
effects were evaluated and compared.
Results: The median overall survival (OS) was 33.2 months. The 3‑year progression‑free survival rates for patients with 
stages I–II, III, and IV diseases were 81.0% (68/84), 65.0% (39/60), and 0% (0/6), respectively; the 3‑year OS rates were 
90.5% (76/84), 85.0% (51/60), and 16.7% (1/6), respectively. Vaginal bleeding was controlled within the median time of 
4.0 days. One month after treatment, 97.3% of patients achieved short‑term local control. The local recurrence rates 
for patients with stages I–II, III, and IV disease were 4.8% (4/84), 11.7% (7/60), and 33.3% (2/6), respectively, and the 
occurrence rates of distant metastasis were 16.7% (14/84), 25.0% (15/60), and 100.0% (6/6), respectively. Cancer stage, 
tumor size, and lymph node metastasis were identified as prognostic risk factors, but only lymph node metastasis was 
found to be an independent prognostic factor. The most common adverse effects during treatment were grades 1 
and 2 irradiation‑related proctitis and radiocystitis.
Conclusion: For patients with cervical cancer, neutron brachytherapy combined with external‑beam radiotherapy 
plus concurrent chemotherapy produces a rapid response and greatly improves local control and long‑term survival 
rates with tolerable adverse effects.
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Background
Cervical cancer is the sixth most common cancer in Chi-
nese women [1]. In 2011, 87,982 cases of cervical cancer 
were reported, and the incidence was 13.40 per 10,000 
women in China [1]. The treatment paradigms in the pri-
mary management of cervical cancer are well established, 
with early lesions being treated surgically or with brachy-
therapy alone [2] and locally advanced lesions being man-
aged with concurrent chemoradiotherapy [3, 4]. The 5-year 
survival rate of patients with stage II or III disease who 
receive concurrent chemoradiotherapy ranged from 53% to 
74%; however, the 5-year survival rate of patients with stage 
IV disease was only 20% to 30% [5]. Different treatment 
algorithms affect surviving women to varying degrees, and 
radiotherapy is associated with longer-term adverse effects 
than surgery or chemotherapy [6, 7]. Several studies have 
shown that adding brachytherapy to the treatment proto-
col results in prolonged survival for patients with cervical 
cancer [8–11]. Studies have also shown that nearly each 
radiotherapy protocol option for so-called radio-resistant 
tumors is more efficacious than photon brachytherapy; 
therefore, to improve the curability of cervical cancer, new 
types of radiation should be studied [12].
Californium-252 (252Cf) was first identified in the debris 
from a thermonuclear test explosion in 1950 [12]. The 
discovery raised the possibility of using fast neutrons in 
brachytherapy, with the neutron interaction being concen-
trated directly in the tumor tissues that need irradiation. 
It has been suggested that the resistance of tumor cells 
to gamma-ray radiation can be overcome by administer-
ing radiotherapy with neutron emitters [13, 14]. Several 
pilot studies have found that 252Cf brachytherapy for cer-
vical cancer offers advantages over traditional gamma-ray 
radiation [12–16]. In the mainland of China, many patients 
with cervical cancer have been treated with 252Cf neutron 
brachytherapy (NBT) [17]. However, the widespread use 
of 252Cf NBT in the mainland of China has been limited by 
insufficient clinical data regarding its efficacy and safety.
In this retrospective clinical study, we analyzed the 
long-term survival, adverse effects, metastasis, and 
recurrence in 150 patients with cervical cancer who were 
treated in 2010 with 252Cf NBT combined with external-
beam radiotherapy (EBRT) plus concurrent chemother-
apy at the Armed Police Hospital of Guangdong Affiliated 
with Guangzhou Medical University.
Methods
Patient population
Between January 2010 and December 2010, more than 
400 patients with primary cervical cancer were treated 
with concurrent chemotherapy combined with 252Cf 
NBT and EBRT at the Armed Police Hospital of Guang-
dong Affiliated with Guangzhou Medical University, 
Guangzhou, China. The patients with newly diagnosed 
cervical cancer and without previous treatment were 
selected. Patients with any of the following conditions 
were excluded: (1) bone marrow suppression (periph-
eral blood leukocyte count  <3  ×  109/L and platelet 
count  <7  ×  109/L); (2) uncontrolled acute or sub-acute 
pelvic inflammatory disease; (3) extensive tumor, quali-
tative cachexia, or uraemia; (4) acute hepatitis or uncon-
trolled severe cardiovascular disease; and (5) pregnancy, 
a history of malignancies, or previous treatment with 
chemotherapy, surgery, or radiotherapy.
Cervical cancer was staged according to 1997 Interna-
tional Federation of Gynecology and Obstetrics recom-
mendations. Prior to treatment, all patients underwent 
physical examination, gynecologic examination, chest 
computed tomography (CT), electrocardiography, and 
abdominal and urinary system B ultrasound. Also prior 
to treatment, tumor size and lymph node status were 
determined with magnetic resonance imaging (MRI) or 
CT. Lymph node metastasis was defined as the status that 
lymph node exhibited loss of oval shape and were greater 
than 1.0  cm in diameter. The Academic Committee of 
the Armed Police Hospital of Guangdong Affiliated with 
Guangzhou Medical University approved this study.
252Cf NBT
In the Department of Oncology at the Armed Police Hos-
pital of Guangdong Affiliated with Guangzhou Medi-
cal University, 252Cf intracavitary after-loading NBT was 
performed using an LZH-1000 NBT instrument (Model 
ZH-1000; Linden Science and Technology, Shenzhen, 
Guangdong, China). The 252Cf neutron source of this unit 
was 712.787–503.881  µg with a half-life of 2.65  years, 
involving a decay process that launches neutron and 
gamma rays and has a neutron emission rate of 2.3 mil-
lion neutrons per second, an average energy of 2.14 MeV 
(gamma rays), an average energy of 0.8  MeV (neutron 
rays), and a neutron relative biological effect (RBE) of 
2–3 [18]. The radioactive source used for the patients 
included in the present study was changed in 2010.
Prior to the administration of 252Cf NBT, the patients 
received a rectal barium enema to visualize the rectum, 
and 7  mL of contrast media was injected into a Foley 
catheter through a urine catheter inserted into the blad-
der. A vaginal and rectal bimanual triple diagnosis was 
obtained by observation of the dilated cervix and vagina. 
Then, three passive cavity applicators were inserted into 
the uterine cavity and bilateral fornix, subsequently, the 
vagina was tight packing with gauze. According to the 
tumor size, the applicator was inserted after routine ster-
ilization and was positioned and fixed to the vagina and 
uterine cavity. After the applicator was fixed, orthogonal 
radiographs of the pelvic cavity were acquired to display 
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the position of the applicator and the extent and size of 
the tumor (Fig.  1). Dosimetry was prescribed to “point 
A,” defined by the Manchester system as 2.0 cm superior 
(along the tandem) to the flange abutting the external 
cervical os and 2.0 cm lateral from the axis of the tandem.
Correspondingly, the doses were calculated at stand-
ardized point B, which is located at 5.0  cm from the 
uterine central axis and represents part of the obturator 
lymph nodes as well as the bladder and rectal points.
The dose of 252Cf was calculated in Gy-equivalents (Gy-
eq) according to the following formula:
where Dn is the dose of the neutron component of 252Cf, 
Dγ is the dose of the gamma-ray component of 252Cf, 
RBEn is the relative biological effectiveness of the neu-
trons, and RBEɣ is the relative biological effectiveness of 
the gamma rays.
The RBE of the neutron component of 252Cf for the 
tumor tissue was estimated to be 6 [18–20]. The doses at 
point A were calculated assuming a high-dose-rate deliv-
ery of 6 Gy-eq for each patient per fraction, administered 
once per week, to deliver a total dose of 30 Gy. Optimized 
treatment plans were based on tumor size; the exposure 
of the bladder and rectum was no more than 60% of the 
dose at point A.
External pelvic irradiation
The use of CT-based treatment planning and conformal 
blocking was considered the standard methods for EBRT. 





= Dn× RBEn+ Dγ × RBEγ
extent and size of the tumor. The external-beam radiation 
administered to the patients was produced by standard 
X-ray beams generated from a medical linear accelerator 
with an energy level of 8 MeV (Elekta, Stockholm, Sweden).
The applied dose was delivered at two opposite fields as 
divided doses to full and split fields of the pelvis, extend-
ing to the para-aortic lymph nodes. The anterior edge of 
the lateral fields included the external iliac lymph nodes, 
and the posterior edge included the presacral lymph 
nodes. In general, the upper boundary was the fifth lum-
bar vertebra; however, for patients with documented com-
mon iliac and/or para-aortic nodal involvement, the upper 
boundary reached the level of the renal vessels. The lower 
boundary was located on the lower edge of the obtura-
tor or ischial tuberosity, and the left and right bounda-
ries were 1.5–2.0  cm beyond the outside of the pelvis. 
The typical size ranged from 15.0 to 17.0 cm. For patients 
with negative lymph nodes (i.e., the lymph nodes without 
metastasis as determined by CT and/or MRI scans), the 
irradiation volumes included the gross primary cervical 
tumor; the uterus; the paracervical, parametrial, and uter-
osacral regions; and the entire external iliac, internal iliac, 
and obturator nodal basins. For patients with bulk tumors 
(diameter  >4.0  cm) or suspected nodes confined to the 
low pelvis, the irradiation volume was extended to cover 
the common iliacs. For patients with documented com-
mon iliac and/or para-aortic nodal involvement, the irra-
diation field was extended to the level of the renal vessels. 
The prescribed radiation dose for the clinical target was 
a daily fraction of 2.0 Gy, administered 5 days per week; 
a variation of up to 5% was considered acceptable. The 
Fig. 1 Schematic representation of californium‑252 (252Cf ) neutron brachytherapy (NBT). Contrast media was injected into a Foley catheter. Then, 
three passive cavity applicators were inserted into the uterine cavity and bilateral fornix; the applicator that delivers 252Cf was inserted and fixed to 
the vagina and uterine cavity. Finally, orthogonal radiographs of the pelvic cavity were acquired from the antero‑posterior (a) and lateral (b) direc‑
tions. The yellow arrows indicate the cavity applicators
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total dose administered to the whole pelvis was 45–50 Gy. 
For patients with bulk tumors, the parametrial disease 
area was further irradiated with an additional boost of 
8–10 Gy in 4–5 fractions, and the dose to the gross pelvic 
nodes reached 60–65 Gy.
Above all, the total target doses administered to all 
patients during the treatment were 85 Gy-eq at point A 
and approximately 60 Gy-eq at point B. In other words, 
EBRT was initiated (1.8–2.0 Gy/day) for the total dose at 
point A. Then, NBT at a total dose of 30 Gy-eq was deliv-
ered. The period during the treatment with 8-MV X-ray 
EBRT and 252Cf NBT was 6 weeks.
Amifostine application
To prevent irradiation-related enteritis, all patients 
received 2 mg (20 mL) amifostine, dissolving in saline to a 
concentration of 50 mg/mL, in the rectum for 30–45 min 
once per week [21]. To avoid infection and vaginal peri-
neum contracture, the patients underwent perineal 
douche every day during the radiotherapy for the pelvis 
but not on the day of 252Cf NBT.
Concurrent chemotherapy
During pelvic EBRT, all 150 patients received 40 mg/m2 
cisplatin on days 1, 8, 15, 22, 29 and 36. Prior to chemo-
therapy, anti-emetic drugs, preventive measures, and 
hydration treatments were administered to alleviate 
chemotherapy-related symptoms. Blood tests, blood bio-
chemistry assessments, and gynecologic examinations 
were performed weekly to determine whether the lesions 
had regressed and to evaluate the clinical situation.
Evaluation and follow‑up
After completion of therapy, all patients were followed 
up 1  month after treatment, then every 3  months up 
to 1  year, and thereafter every 6  months up to 3  years 
through outpatient department visits. The patients lost 
to follow-up were classified as censored. The follow-up 
included routine physical examination, blood cell counts, 
pelvic examination, MRI of the abdomen and pelvis, 
chest X-ray radiography, abdominal B ultrasound, cer-
vical/vaginal cytology, and row biopsy for residual or 
recurrent local cervical tumors.
According to World Health Organization standards 
related to therapeutic effects in solid tumors, short-term 
local curative effects observed within 1 month after treat-
ment were categorized as complete response (CR), partial 
response (PR), stable disease (SD), and progressive dis-
ease (PD). For the patients with CR and PR, the treatment 
was considered effective. During the first month after 
treatment, the tumor masses in the abdomen and pelvis 
were evaluated through MRI. Progression-free survival 
(PFS) was calculated from the date when radiotherapy 
was administered to the date of local recurrence, distant 
metastasis, death, or the last follow-up. Overall survival 
(OS) was calculated from the date when the treatment of 
the patients was administered to the date of death or the 
last follow-up. The irradiation-related adverse effects were 
graded according to the 1995 Radiation Therapy Oncol-
ogy Group/European Organization for Research and 
Treatment of Cancer (RTOG/EORTC) guidelines. RTOG 
acute radiation morbidity criteria were used for the evalu-
ations conducted during irradiation or within the first 
90  days after treatment. RTOG late radiation morbidity 
criteria were used to evaluate adverse effects observed 
after completion of irradiation. Toxicity classified as grade 
3 or higher was considered severe. The irradiation-related 
adverse effects included bone marrow suppression, gas-
trointestinal reactions, irradiation-related enteritis, intes-
tinal obstruction, intestinal fistula, irradiation-related 
cystitis, and urinary fistula [7, 9, 13, 15].
Statistical analysis
All data were analyzed using SPSS 17.0 software (SPSS, 
Inc., Chicago, IL, USA). Kaplan–Meier plots were used 
for survival analysis and Cox regression was used for 
the multivariate analysis. Unless otherwise stated, all 
reported P values were two-tailed. P values less than 0.05 
were considered statistically significant.
Results
Patient characteristics
We included 150 patients with cervical cancer in this ret-
rospective study. The patients ranged in age from 27 to 
79 years (median, 50 years). Other patient characteristics 
are listed in Table 1.
Control of vaginal bleeding
Of the 150 included patients, 116 (77.3%) exhibited 
symptoms of vaginal bleeding, including 2 (1.3%) with 
stage I cervical cancer, 35 (23.3%) with stage II disease, 
73 (48.7%) with III disease, and 6 (4.0%) with stage IV 
disease. This irregular vaginal bleeding was controlled 
within 3–6  days (median, 4  days). Because very few 
patients had stage I disease, we combined the patients 
with stage I and stage II disease into one group for data 
analysis.
Short‑term local curative effects
All 150 patients were followed up 1 month after treatment. 
After all 150 patients underwent 252Cf NBT combined with 
EBRT plus concurrent chemotherapy, 138 (92.0%) reached 
CR, 8 (5.3%) reached PR, 4 (2.7%) had stable disease, and 
none had PD. Overall, 252Cf NBT resulted in a short-term 
local effective rate (CR + PR) of 97.3%. Analysis of patients 
with a tumor ≤4.0 cm in diameter showed a reduction in 
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tumor mass to 50% of the original volume after one cycle 
of 252Cf NBT. It took 5–16 days (median, 9.5 days) for these 
patients to achieve PR. For patients with a tumor >4.0 cm 
in diameter, the tumor began to shrink after two cycles of 
252Cf NBT. It took 5–23  days (median, 18  days) for these 
patients to achieve a CR or PR state.
Survival
During the 3-year follow-up period, 12 patients were lost 
to follow-up and 24 patients died. Of the 24 patients who 
died before the last follow-up, 2 died within 1  year after 
the first treatment, 11 died in the second year, and 11 died 
in the third year. The 3-year median overall survival time 
was 33.2 months (range, 7.8–36.0 months). The PFS rates 
for patients with stages I–II, III, and IV cervical cancer 
were 81.0% (68/84), 65.0% (39/60), and 0% (0/6), respec-
tively; and the 3-year OS rates for these patients were 90.5% 
(76/84), 85.0% (51/60), and 16.7% (1/6), respectively (Fig. 2).
Factors related to the prognosis of patients with cervical 
cancer
Univariate analysis showed that stage, tumor size, and 
lymph node metastasis were factors that significantly 
affected prognosis (Table  2). However, Cox analysis 
showed that only lymph node metastasis was an inde-
pendent prognostic factor (Table 3).
Local recurrence and distant metastasis
The cancer recurrence rates in the pelvis for patients 
with stages I–II, III, and IV diseases were 4.8% (4/84), 
11.7% (7/60), and 33.3% (2/6), respectively. The occur-
rence rates of distant metastasis for patients with stages 
Table 1 Characteristics of  150 patients with  cervical can-
cer
FIGO International Federation of Gynecology and Obstetrics
Characteristic No. of patients (%)
Stage (FIGO)
 I 2 (1.3)
  IA 0 (0.0)
  IB 2 (1.3)
 II 82 (54.7)
  IIA 13 (8.7)
  IIB 69 (46.0)
 III 60 (40.0)
  IIIA 15 (10.0)
  IIIB 45 (30.0)
 IV 6 (4.0)
  IVA 4 (2.7)
  IVB 2 (1.3)
Histopathologic type
 Squamous cell carcinoma 146 (97.3)
 Adenocarcinoma 3 (2.0)
 Clear cell carcinoma 1 (0.7)
Pre‑treatment tumor size (cm)
 ≤4.0 85 (56.7)
 >4.0 65 (43.3)
Lymph node metastasis
 Yes 49 (32.7)
 Not 73 (48.7)
 Unknown 28 (18.6)
Fig. 2 Kaplan‑Meier curves of 3‑year progression‑free survival and 
3‑year overall survival for 150 patients with cervical cancer who were 
treated with 252Cf NBT combined with external‑beam radiotherapy 
(EBRT) plus concurrent chemotherapy. a Progression‑free survival;  
b overall survival
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I–II, III, and IV diseases were 16.7% (14/84), 25.0% 
(15/60), and 100% (6/6), respectively. All 24 patients 
who died had recurrence or metastasis within 3  years; 
of these patients, 3 experienced single local recurrence, 
and 21 had distant metastasis. Among the 24 patients 
who died, 18 had distant metastasis in the bone, 18 in 
the left supraclavicular lymph nodes, 17 in the lung, 17 
in the para-aortic lymph nodes, 16 in the liver, and 12 in 
the inguinal nodes.
Acute and late adverse effects
We retrospectively analyzed the occurrence rate of acute 
and late irradiation-related adverse effects in the 150 
patients with cervical cancer. Immediately after treat-
ment, 11 (7.3%) experienced irradiation-related proctitis, 
with symptoms of tenesmus, down-bearing distention 
of the anus, and diarrhea; 6 patients (4.0%) experienced 
acute radiocystitis, with symptoms of increased urinary 
frequency and urgency and pain while urinating; and 1 
(0.7%) experienced acute hematuria. The reactions and 
late adverse effects observed after NBT are presented in 
Table  4. Late adverse effects primarily occurred in the 
intestinal tract and urinary system. According to RTOG/
EORTC scoring criteria, the most common adverse 
effects were irradiation-related proctitis and radiocystitis.
Discussion
Our retrospective study assessed the long-term treat-
ment outcomes of cervical cancer patients treated with 
252Cf NBT combined with EBRT plus concurrent chemo-
therapy. We found that, for the patients with stages I–II, 
III, and IV diseases, the PFS rate was 81.0%, 65.0% and 
0%, respectively; the 3-year OS rate was 90.5%, 85.0% and 
16.7%, respectively; the local recurrence rate was 4.8%, 
11.7% and 33.3%, respectively; and the occurrence rate 
of distant metastasis was 16.7%, 25.0% and 100%, respec-
tively. The most common adverse effects during treat-
ment were irradiation-related proctitis and radiocystitis.
For over 100  years, brachytherapy has been an essen-
tial component in the treatment of cervical cancer [4], 
and gamma ray-emitting sources, such as cobalt-60 
(60Co), iridium-192 (192Ir), and caesium-137 (137Cs), are 
widely used in brachytherapy [17]. These radionuclides 
create low-linear energy transfer (LET) radiation with 
poor efficacy against hypoxic tumor cells [22]. Tumor 
cells are resistant to conventionally fractionated irradia-
tion because they present a high degree of DNA damage 
repair, but these cells are not resistant to high-LET irra-
diation (such as neutron radiation), which kills the cells 
with single-hit, non-repairable damage [23]. NBT is a 
form of high-LET radiotherapy that has been shown to 
Table 2 Univariate analysis of  factors related to  3-year 
overall survival rate of cervical cancer patients
Patients with unknown lymph node status were excluded from the univariate 
analysis with the characteristic of lymph node metastasis
HR hazard ratio, CI confidence interval, FIGO International Federation of 
Gynecology and Obstetrics
Characteristic P value HR 95% CI
Stage (FIGO) <0.001
 III vs. I–II 0.181 1.95 0.74–5.13
 IV vs. I–II <0.001 20.60 6.11–69.39
Pre‑treatment tumor size (≤4.0 cm 
vs. >4.0 cm)
<0.001 0.17 0.06–0.4
Lymph node metastasis (yes vs. no) <0.001 0.02 <0.01–0.17
Age (per 1‑year increase) 0.850 1.01 0.96–1.05
Table 3 Multivariate analysis results for  overall survival 
rate of  cervical cancer patients using the Cox multiple 
regression method
Patients with unknown lymph node status were excluded from the multivariate 
analysis with the characteristic of lymph node metastasis
HR hazard ratio, CI confidence interval, FIGO International Federation of 
Gynecology and Obstetrics
Characteristic P value HR 95% CI
Stage (FIGO)
 III vs. I–II 0.398 0.63 0.21–1.85
 IV vs. I–II 0.271 2.14 0.55–8.28
Pre‑treatment tumor size (≤4.0 cm 
vs. >4.0 cm)
0.908 3.11 0.82–7.90
Lymph node metastasis (yes vs. no) 0.001 36.32 4.65–283.92
Table 4 Irradiation-related adverse effects in  150 patients with  cervical cancer who were treated with  californium-252 
neutron brachytherapy combined with external-beam radiotherapy
All values are presented as number of patients followed by percentage in parentheses
NA not applicable
Adverse effect Total Grade I Grade II Grade III Grade IV
Irradiation‑related proctitis 150 (100) 134 (89.3) 13 (8.7) 2 (1.3) 1 (0.7)
Radiocystitis 148 (98.7) 130 (86.7) 11 (7.3) 7 (4.7) 0 (0.0)
Rectovaginal fistula 3 (2.0) NA NA NA NA
Down‑bearing distention of the anus 75 (50.0) NA NA NA NA
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be effective in killing radio-resistant cancer cells [5, 7]. 
In 1979, Maruyama et  al. [20] published the first thera-
peutic results of the application of 252Cf NBT combined 
with external gamma-ray radiation for the intracavitary 
treatment of cervix cancer. Several studies have shown 
that 252Cf NBT, as a treatment of cervical cancer, is sig-
nificantly more effective than conventional low-LET 
irradiation [14, 18, 21]. Janulionis et  al. [24] conducted 
a long-term retrospective study comparing the out-
comes of 252Cf and 60Co isotope intracavitary brachy-
therapy combined with brachytherapy in the treatment 
of patients with stage IIB cervical cancer and found 
similar OS rates in both treatment groups. However, the 
rate of tumor recurrence was significantly lower in the 
252Cf group than in the 60Co intracavitary brachytherapy 
group. Tacev et al. [15] retrospectively studied the cura-
tive rate of patients with stages IIB and IIIB cervical 
cancer after 252Cf NBT supplemented with radium-226 
(226Ra) or 137Cs intracavitary brachytherapy or with only 
gamma-ray radiation (226Ra or 137Cs); they observed sig-
nificantly improved 5-year survival rates, regardless of 
tumor stage, for patients treated with 252Cf NBT com-
pared with those who received conventional treatment. 
One trial of 206 patients with stage III cervical cancer 
who were treated with gamma-ray irradiation reported 
the 3-year OS rate ranging from 66.3% to 69.6%, which is 
lower than that found in our study (85.0%) [25]. A clini-
cal study of stage IIB cervical cancer patients who were 
treated with low dose rate 192Ir intracavitary brachyther-
apy found that the response to radiotherapy was a strong 
predictor of local control, with 82% of patients continu-
ing to have local control of the pelvis after the initial CR 
[26].
However, the local control rate (82%) reported by 
Budrukkar et  al. [26] was lower than that in our study 
(97.3%). In another study, 32 patients with mainly 
advanced-stage squamous cell carcinoma received 
gamma-ray brachytherapy, and the 5-year OS, PFS, and 
local control rates were 75%, 68.5% and 92.8%, respec-
tively [27]. The above-mentioned findings and those 
obtained in our study showed the advantage of the neu-
tron source of 252Cf in brachytherapy for cervical cancer, 
mainly by overcoming tumor resistance to conventional 
photon irradiation; in particular, 252Cf NBT combined 
with EBRT was superior in terms of local control rate. 
The superiority of the neutron source of 252Cf in brachy-
therapy for cervical cancer may be attributed to the fact 
that high-LET irradiation causes irreversible changes 
in cellular systems [18, 28, 29] and that the 252Cf neu-
tron ray demonstrates a high-energy deposition rate and 
accurate positioning, exhibits only a small dependence 
on oxygen, and results in only slight damage to normal 
tissue [30]. As a result, 252Cf neutron NBT is superior to 
traditional gamma ray-emitting sources used in intracav-
itary brachytherapy for cervical cancer.
In patients with cervical cancer, locoregional recur-
rence and distant metastasis are the major causes of 
clinical failure, followed by local-distant recurrence and 
para-aortic lymph node metastasis. Patients with recur-
rent lesions in the irradiation field may experience central 
or peripheral recurrence. However, once patients develop 
distant metastases, their prognoses are very poor. In our 
present study, 24 patients died within 3  years, and the 
most common sites of metastasis were the lung, bone, 
and liver.
In this study, univariate analysis showed that tumor 
size, lymph node metastasis, and tumor stage were asso-
ciated with OS. However, Cox analysis showed that only 
lymph node metastasis was an independent prognostic 
factor. We did not find a significant association of patho-
logic type with patient prognosis because the vast major-
ity (146 of 150) of patients had squamous cell carcinoma 
and only 4 patients had adenocarcinoma or clear cell car-
cinoma. Therefore, additional larger-scale clinical data 
analysis is necessary.
In this study, the adverse effects of 252Cf NBT were 
mainly irradiation-related proctitis and cystitis; spe-
cifically, the most common occurrence rates of grade 1 
irradiation-related proctitis and cystitis were 89.3% and 
86.7%, respectively. The short-term adverse effects asso-
ciated with 252Cf NBT include vaginal stenosis, stenosis of 
the rectum, and rectovaginal fistula. Of the 150 patients 
included in this study, 3 (2.0%) developed rectovaginal 
fistulas. Our study showed that the adverse effects that 
patients with cervical cancer who underwent 252Cf NBT 
experienced were minimal and tolerable. Patients with 
grade 1 to 2 adverse effects required either no treatment 
or simple outpatient management. Patients with moder-
ate to severe morbidity (RTOG grades 3–5), who experi-
enced symptoms that were distressing enough to reduce 
their quality of life, required more intense management 
of adverse effects. These adverse effects might have been 
related to the long duration of urethral catheter place-
ment during each treatment (because the neutron source 
was in its second half-life, each treatment lasted 3 h).
To reduce the occurrence rate of irradiation-related 
enteritis and cystitis, we administered amifostine as a 
rectal suspension once per week. Several studies have 
shown that amifostine protects various cells from irradia-
tion damage by removing oxygen radicals and detoxify-
ing the reactive metabolites of cytotoxic agents [21, 31, 
32]. Furthermore, amifostine induces endothelial cell 
proliferation and the ensuing neovascularization, which 
contributes to wound healing [33, 34]. It is important to 
maintain the proper distance between the vagina and the 
bladder in the anterior direction and the proper distance 
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between the vagina and the rectum in the posterior 
direction. In a study of patients undergoing high-dose-
rate 192Ir intracavitary brachytherapy, Ferrigno et al. [35] 
reported that the 5-year occurrence rates of late adverse 
effects in the rectum, bladder, and small bowel were 16%, 
11% and 14%, respectively. Compared with these data, 
the occurrence rates of late adverse effects in the present 
study were markedly lower (Table 4).
Since 1999, concurrent chemotherapy with irradia-
tion has been the standard treatment of cervical cancer 
[36, 37]. For patients with stage IIB and more advanced 
cervical cancer, the results of many randomized clinical 
studies on the use of synchronous chemotherapy and 
radiotherapy showed that these treatments significantly 
improved local control and survival rates and that irradi-
ation-related adverse effects were tolerated [37].
Our study did have several limitations. First, the data-
base of the irradiation-related adverse effects was not 
very comprehensive and detailed because of the retro-
spective nature of the study. Second, this study did not 
include a control group that was treated with a different 
type of radiation. Third, our clinical data regarding cervi-
cal cancer treatment using 252Cf NBT were obtained from 
a single center. Multicenter trials should be conducted 
to further standardize treatment programs. Additional 
studies are needed to determine the optimal fractiona-
tion schedule of 252Cf NBT as well as optimal approaches 
to reduce the adverse effects of radiotherapy and increase 
tumor response to radiotherapy, thereby improving the 
prognosis of patients with cervical cancer.
Conclusions
In summary, 252Cf NBT combined with EBRT plus con-
current chemotherapy as a treatment of cervical cancer 
offers a highly effective therapeutic modality with toler-
able adverse effects and can improve the local control 
and long-term survival rates of patients. OS of cervical 
cancer patients treated with 252Cf NBT combined with 
EBRT plus concurrent chemotherapy was associated with 
tumor size, tumor stage, and lymph node metastasis.
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